An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

The female reproductive system includes internal and external organs, each designed to carry out varying functions. Learn more about the anatomy of this system.

Camizestrant is a degrader of estrogen receptors, which leads to a cessation of cancer growth and proliferation. It delays breast cancer progression in people with advanced or metastatic disease. This ...

There are several associated risk factors, including hereditary and acquired genetic mutations (alterations in the DNA), and the influence of hormones. Learn More Causes and Risk Factors of Ovarian ...

Researchers found no link between hormone therapy and gliomas, the most common brain tumors in adults, according to results of a new study published recently in the journal Menopause. “Compared with ...

We present a case of a woman who developed OHSS due to an FSH-secreting pituitary adenoma ... thereby avoiding multiple therapeutic procedures for ovarian cysts and ultimately also restoring ...

This approval marks a significant advancement in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The efficacy of datopotamab ...

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal ...

Siteman Cancer Center at Washington University. But too much estrogen over a lifetime can lead to the formation and growth of cancerous cells. Over time, there have been several population-level ...

A comprehensive review appearing in Frontiers of Medicine provides insights into the mechanisms linking obesity to cancer risk and ... such as elevated estrogen levels, contribute to the ...